Replies to post #194840 on Avid Bioservices Inc (CDMO)

[biopharm]

Scott Antonia : Peregrine Pharmaceuticals KOL : .... now this is not directly related to Bavituximab/PS Targeting, but it does show his relation with BMS

Nivolumab plus chemo less than stellar

Nov 7, 2014

CHICAGO– Combining the PD-1 checkpoint inhibitor nivolumab with first-line chemotherapy for advanced non–small cell lung cancer produced responses no better than those previously reported for chemotherapy alone, according to results of CheckMate 012.
..
Overall, responses were independent of programmed death-1 (PD-1) status and toxicity was manageable.

“It is my opinion that these data support further development of concurrent bimodality therapies,” Dr. Antonia from the Moffitt Cancer Center, Tampa, said at the Chicago Multidisciplinary Symposium in Thoracic Oncology, where the data were presented.
..
Nivolumab is under review for non–small cell lung cancer (NSCLC) in Europe, and drug developer Bristol-Myers Squibb is expected to complete submission for third-line, pretreated squamous cell NSCLC in the United States by year’s end.

Nivolumab is already under priority review in the United States for pretreated advanced melanoma, and it became the world’s first approved PD-1 inhibitor with the July 2014 approval for unresectable melanoma in Japan, where it is sold under the trade name Opdivo.

PD-1 inhibitors have proven to be very active drugs in NSCLC, raising the inevitable question of whether they would be even more effective when combined with chemotherapy.

http://www.chestphysician.org/home/article/checkmate-012-nivolumab-plus-chemo-less-than-stellar/601e3ab3e674980e48b5ed530d6e27e4.html